drugset / Trial / NCT00019890
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Treatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have high-risk stage III or completely resected metastatic melanoma.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dendritic cell-gp100-MART-1 antigen vaccine | Vaccine | — | Intrathecal |
| Background | sargramostim | Protein / enzyme biologic | — | — |